Nasus Pharma (NSRX) Shares Outstanding (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Shares Outstanding (Entity) came in at $9.0 million in Q4 2025, up 22.44% YoY from $7.4 million in Q4 2024, and up 22.44% on a QoQ basis from $7.4 million in Q2 2025.
Nasus Pharma (NSRX) Shares Outstanding (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Shares Outstanding (Entity) data on file, last reported at $9.0 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 22.44% year-over-year to $9.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (up 22.44% YoY) and the FY2025 annual result came in at $9.0 million, up 22.44% from the prior year.
- Shares Outstanding (Entity) grew to $9.0 million in Q4 2025, from $7.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $9.0 million in Q4 2025 to a low of $7.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - | 8.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.01 Mn |
| Jun 30, 2025 | 7.36 Mn |
| Dec 31, 2024 | 7.03 Mn |